| Metric | Value (₹ Cr) | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue | 2.3K | 14.2% | 9.3% |
| Total Income | 2.4K | 12.3% | 11.8% |
| Expenditure | 2.3K | 11.2% | 10.0% |
| PBT | 120.16 | 13.5% | 61.9% |
| Net Profit | 102.28 | 6.8% | 54.7% |
| OPM | 5.96% | 1.81pp | 0.91pp |
| NPM | 4.26% | 0.25pp | 1.18pp |
| EPS | 5.45 | 8.7% | 48.1% |
Godrej Agrovet FY26 Revenue up 9% to ₹10,233 Cr, PBT up 17%
30 Apr 2026 · 30 Apr, 10:12 pm
Summary
Godrej Agrovet Limited announced strong financial results for the fourth quarter and full year ended March 31, 2026. For FY26, consolidated revenue from operations reached ₹10,233 crore, reflecting a 9% year-on-year growth, while profit before tax (excluding non-recurring & exceptional items) surged by 17% to ₹569 crore. The fourth quarter also demonstrated robust performance, with consolidated revenue growing 9.3% to ₹2,333 crore and PBT (excluding non-recurring & exceptional items) increasing by 17.6% to ₹87 crore. Mr. Sunil Kataria, CEO & MD, attributed this success to the company's strategy of moving towards a value-added portfolio, disciplined execution, and a sharp focus on improving the quality of earnings, with Oil Palm, Animal Nutrition, and Astec LifeSciences being key growth drivers.
Key Highlights
- 1
FY26 consolidated revenue from operations reached ₹10,233 crore, marking a 9% year-on-year growth compared to ₹9,383 crore in FY25.
- 2
Profit before tax (excluding non-recurring & exceptional items) for FY26 grew by a robust 17% year-on-year to ₹569 crore, up from ₹485 crore in FY25.
- 3
Q4 FY26 consolidated revenue from operations increased by 9.3% year-on-year to ₹2,333 crore, compared to ₹2,134 crore in Q4 FY25.
- 4
Q4 FY26 Profit before tax (excluding non-recurring & exceptional items) rose by 17.6% year-on-year to ₹87 crore, from ₹74 crore in Q4 FY25.
- 5
The Oil Palm business delivered an outstanding performance in FY26 with strong volume growth, peak oil recovery, and margin expansion, resulting in a ~68% year-on-year growth in segment results.
- 6
Animal Nutrition business outperformed with healthy volume-led growth of ~12% year-on-year in FY26 and ~15% in Q4 FY26, supported by favorable commodity positions and cost-optimization initiatives.
- 7
Astec LifeSciences achieved a strong turnaround in FY26, reaching EBITDA break-even with a sharp reduction in losses, driven by improved volumes, better realizations, and higher capacity utilization.
Management Comments
Mr. Sunil Kataria
FY 2025–26 marked a strong year of delivery for Godrej Agrovet Limited, with consolidated revenues surpassing ₹10,000 crore, growing by 9% year-on-year, while profitability registered a robust 17% growth. This performance underscores the strength of our growth strategy of moving towards value-added portfolio, disciplined execution and sharp focus on improving the quality of earnings. During the year, we delivered a meaningful reduction in working capital, which strengthened operating cash flows and translated into a tangible improvement in ROCE. The year was led by exceptional performance in our Oil Palm and Animal Nutrition businesses. The Oil Palm business delivered an outstanding performance with strong volume growth, peak oil recovery and margin expansion, while Animal Nutrition outperformed through healthy volume-led growth supported by favorable commodity positions and sustained cost-optimization initiatives. Astec LifeSciences delivered a strong turnaround in FY26, achieving EBITDA break-even with a sharp reduction in losses, supported by improved volumes, better realizations and higher capacity utilization across the Enterprise and CDMO businesses. In Poultry & Processed Foods, increased salience of branded products enhanced the quality and sustainability of earnings, with year-on-year improvement in profitability. The conscious shift towards higher-quality branded offerings led to a calibrated moderation in revenues, reinforcing the long-term stability of the business model. Our Dairy business was adversely impacted by unseasonal rains in Q1 FY26, which temporarily affected demand for value-added products, along with elevated milk procurement prices during the year. Despite these headwinds, focused operational initiatives and efficiency improvements supported the ongoing turnaround and strengthened the foundation for future growth.
Informational and educational content only. Not investment advice.